Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment of Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: Five- Year Follow-Up Results From CheckMate649 : Episode 7

Key Takeaways and Future in Advanced Gastric Cancer Treatment

February 28, 2025

By David H. Ilson, MD, PhD
Sunnie Kim, MD

Opinion

Video

Panelists discuss how future analyses in advanced gastric cancer should assess long-term survival, real-world outcomes, biomarkers for response, resistance mechanisms, and patient selection for nivolumab plus chemotherapy. Evaluating these factors will optimize treatment strategies and confirm its role across diverse populations.

EP: 1.Treatment Landscape and Unmet Needs in Advanced Gastric Cancers

EP: 2.CheckMate649 5-Year Follow-Up, Study Design, and Efficacy Results

EP: 3.Evaluating Long-Term Outcomes and Personalized Treatment Strategies in Advanced Gastrointestinal Cancers

EP: 4.Assessing the Long-Term Safety and Efficacy of Nivolumab Plus Chemotherapy for Broader Clinical Adoption in Advanced GI Cancers

EP: 5.Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers

EP: 6.Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers

Now Viewing

EP: 7.Key Takeaways and Future in Advanced Gastric Cancer Treatment

EP: 8.Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

What are some key takeaways from this discussion?
What will be important to evaluate in future analyses in advanced gastric cancers?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!